The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves

The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer

(2018) Tuo Li et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A2AAdenosine Receptor Gene Deletion or Synthetic A2AAntagonist Liberate Tumor-Reactive CD8+T Cells from Tumor-Induced Immunosuppression

(2018) Jorgen Kjaergaard et al.   JOURNAL OF IMMUNOLOGY

Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

(2018) Shivani Srivastava et al.   JOURNAL OF IMMUNOLOGY

CAR T cell immunotherapy for human cancer

(2018) Carl H. June et al.   SCIENCE

STINGing Antitumor Immunity into Action

(2018)   Cancer Discovery

Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)

(2018) Young Kwang Chae et al.   Journal for ImmunoTherapy of Cancer

Dual enhancement of T and NK cell function by pulsatile inhibition of SHIP1 improves antitumor immunity and survival

(2017) Matthew Gumbleton et al.   Science Signaling

Rare Tumors in Kids May Respond to Tazemetostat

(2017)   Cancer Discovery

Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases—a phase II, single centre, randomised, pilot study

(2017) Tavis Read et al.   BMJ Open

Dual enhancement of T and NK cell function by pulsatile inhibition of SHIP1 improves antitumor immunity and survival

(2017) Matthew Gumbleton et al.   Science Signaling

TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells

(2016) Hung C. Tran et al.   CLINICAL CANCER RESEARCH

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN

(2016) Laura Q.M. Chow et al.   CLINICAL CANCER RESEARCH

Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition

(2016) Srimoyee Ghosh et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PI3Kγ is a molecular switch that controls immune suppression

(2016) Megan M. Kaneda et al.   NATURE

Lipid phosphatase SHIP2 functions as oncogene in colorectal cancer by regulating PKB activation

(2016) Elmer Hoekstra et al.   Oncotarget

Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma

(2016) Andrew R Conery et al.   eLife

Innate Immune Recognition of Cancer

(2015) Seng-Ryong Woo et al.   Annual Review of Immunology

Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma

(2015) A. H. Rook et al.   BLOOD

Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma

(2015) Q. Yang et al.   CLINICAL CANCER RESEARCH

Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337)

(2015) G. N. Dietsch et al.   CLINICAL CANCER RESEARCH

Big opportunities for small molecules in immuno-oncology

(2015) Jerry L. Adams et al.   NATURE REVIEWS DRUG DISCOVERY

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

(2015) Idit Sagiv-Barfi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade

(2015) Juan Fu et al.   Science Translational Medicine

Coordinate Expansion of Murine Hematopoietic and Mesenchymal Stem Cell Compartments by SHIPi

(2015) R. Brooks et al.   STEM CELLS

A Phase I Dose-Finding Study of the Novel Toll-like Receptor 8 Agonist VTX-2337 in Adult Subjects with Advanced Solid Tumors or Lymphoma

(2014) D. W. Northfelt et al.   CLINICAL CANCER RESEARCH

Impaired T-cell survival promotes mucosal inflammatory disease in SHIP1-deficient mice

(2014) M Y Park et al.   Mucosal Immunology

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

(2013) J. A. Dubovsky et al.   BLOOD

Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies

(2012) Brenda J. Weigel et al.   AMERICAN JOURNAL OF HEMATOLOGY

The secret ally: immunostimulation by anticancer drugs

(2012) Lorenzo Galluzzi et al.   NATURE REVIEWS DRUG DISCOVERY

The development and immunosuppressive functions of CD4+ CD25+ FoxP3+ regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway

(2012) Akio Ohta et al.   Frontiers in Immunology

Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells

(2011) Barbara Molon et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Application of electron conformational–genetic algorithm approach to 1,4-dihydropyridines as calcium channel antagonists: pharmacophore identification and bioactivity prediction

(2011) Nazmiye Geçen et al.   JOURNAL OF MOLECULAR MODELING

Inhibitor and activator: dual functions for SHIP in immunity and cancer

(2010) William G. Kerr   Annals of the New York Academy of Sciences

SHIP1 Inhibition Increases Immunoregulatory Capacity and Triggers Apoptosis of Hematopoietic Cancer Cells

(2010) R. Brooks et al.   JOURNAL OF IMMUNOLOGY

Targeting Toll-like receptors: emerging therapeutics?

(2010) Elizabeth J. Hennessy et al.   NATURE REVIEWS DRUG DISCOVERY

TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression

(2010) Li Yang et al.   TRENDS IN IMMUNOLOGY

Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2

(2009) A Suwa et al.   BRITISH JOURNAL OF PHARMACOLOGY

Antagonists of the Human A2AAdenosine Receptor. 4. Design, Synthesis, and Preclinical Evaluation of 7-Aryltriazolo[4,5-d]pyrimidines

(2008) Roger J. Gillespie et al.   JOURNAL OF MEDICINAL CHEMISTRY